These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26264175)

  • 21. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
    Ai X; Sun Y; Wang H; Lu S
    Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of computational methods for predicting the effects of missense mutations in human cancers.
    Gnad F; Baucom A; Mukhyala K; Manning G; Zhang Z
    BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S7. PubMed ID: 23819521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
    Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new disease-specific machine learning approach for the prediction of cancer-causing missense variants.
    Capriotti E; Altman RB
    Genomics; 2011 Oct; 98(4):310-7. PubMed ID: 21763417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved feature-based prediction of SNPs in human cytochrome P450 enzymes.
    Li L; Xiong Y; Zhang ZY; Guo Q; Xu Q; Liow HH; Zhang YH; Wei DQ
    Interdiscip Sci; 2015 Mar; 7(1):65-77. PubMed ID: 25792441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
    Jiang J; Greulich H; Jänne PA; Sellers WR; Meyerson M; Griffin JD
    Cancer Res; 2005 Oct; 65(19):8968-74. PubMed ID: 16204070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.
    Banerjee S; Raman K; Ravindran B
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of cancer driver mutations in protein kinases.
    Torkamani A; Schork NJ
    Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).
    Nagalakshmi K; Jamil K; Pingali U; Reddy MV; Attili SS
    Biomarkers; 2014 May; 19(3):198-206. PubMed ID: 24712396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The (non)malignancy of cancerous amino acidic substitutions.
    Talavera D; Taylor MS; Thornton JM
    Proteins; 2010 Feb; 78(3):518-29. PubMed ID: 19787769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and analysis of driver missense mutations using rotation forest with feature selection.
    Du X; Cheng J
    Biomed Res Int; 2014; 2014():905951. PubMed ID: 25250338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.